NCT02648113 (REALITY) is a NA clinical trial of Restrictive transfusion in Myocardial Infarction, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT02648113?

NCT02648113 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT02648113?

Interventions in NCT02648113: Restrictive transfusion, Liberal transfusion, red blood transfusion.

What condition does NCT02648113 study?

NCT02648113 studies Myocardial Infarction, Anemia, Blood Transfusion.

Is NCT02648113 still recruiting?

NCT02648113 is currently completed. Last updated 12 April 2022.

Last reviewed 2022-04-12 · How we verify

NCT02648113: REALITY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cost-effectiveness and Cost-utility of Liberal vs Restrictive Red Blood Cell Transfusion Strategies in Patients With Acute Myocardial Infarction and Anaemia.

Completed NA Last updated 12 April 2022

What this trial tests

NA trial testing Restrictive transfusion in Myocardial Infarction in 668 participants. Completed in 10 September 2020.

Timeline

23 March 2016

Primary endpoint
10 October 2019

10 September 2020

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	668
Start date	23 March 2016
Primary completion	10 October 2019
Estimated completion	10 September 2020
Sites	2 locations across France, Spain

Drugs / interventions tested

Restrictive transfusion
Liberal transfusion
red blood transfusion — full drug profile →

Conditions studied

Myocardial Infarction — all drugs for Myocardial Infarction →
Anemia — all drugs for Anemia →
Blood Transfusion — all drugs for Blood Transfusion →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with Myocardial Infarction or Anemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Anemia in patients with myocardial infarction (MI) is a relatively frequent issue, resulting in poorer outcome. There is equipoise regarding which transfusion strategy is best, and there is an international consensus on the urgent need for a randomized trial. The investigators hypothesize that a "restrictive" transfusion strategy is at least non-inferior to a "liberal" transfusion strategy on 30-day outcomes of MI patients with anemia. Given the costs and risks of transfusion, a cost-effectiveness and cost-utility analysis becomes key to determining the role of each strategy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion.
Carson JL, Stanworth SJ, Roubinian N, Fergusson DA, et al · · 2016 · cited 232× · PMID 27731885 · DOI 10.1002/14651858.cd002042.pub4
Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial.
Ducrocq G, Gonzalez-Juanatey JR, Puymirat E, Lemesle G, et al · · 2021 · cited 183× · PMID 33560322 · DOI 10.1001/jama.2021.0135
Transfusion thresholds for guiding red blood cell transfusion.
Carson JL, Stanworth SJ, Dennis JA, Trivella M, et al · · 2021 · cited 165× · PMID 34932836 · DOI 10.1002/14651858.cd002042.pub5
Transfusion strategies in non-bleeding critically ill adults: a clinical practice guideline from the European Society of Intensive Care Medicine.
Vlaar AP, Oczkowski S, de Bruin S, Wijnberge M, et al · · 2020 · cited 160× · PMID 31912207 · DOI 10.1007/s00134-019-05884-8
Management and prevention of anemia (acute bleeding excluded) in adult critical care patients.
Lasocki S, Pène F, Ait-Oufella H, Aubron C, et al · · 2020 · cited 35× · PMID 32700082 · DOI 10.1186/s13613-020-00711-6
Economic evaluation of restrictive vs. liberal transfusion strategy following acute myocardial infarction (REALITY): trial-based cost-effectiveness and cost-utility analyses.
Durand-Zaleski I, Ducrocq G, Mimouni M, Frenkiel J, et al · · 2023 · cited 10× · PMID 35612990 · DOI 10.1093/ehjqcco/qcac029
Restrictive vs liberal red blood cell transfusion strategies in patients with acute myocardial infarction and anemia: Rationale and design of the REALITY trial.
Ducrocq G, Calvo G, González-Juanatey JR, Durand-Zaleski I, et al · · 2021 · cited 9× · PMID 33405291 · DOI 10.1002/clc.23453
Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support.
Radford M, Estcourt LJ, Sirotich E, Pitre T, et al · · 2024 · cited 8× · PMID 38780066 · DOI 10.1002/14651858.cd011305.pub3

Verify or expand the search:

Other recruiting trials for Myocardial Infarction

Currently open trials in the same condition.

NCT07257198 — Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone · Phase 3 · recruiting
NCT07402642 — Effect of Early Educational Intervention on Cardiovascular Risk Factors After Acute Coronary Syndrome · NA · recruiting
NCT07301034 — A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, · Phase 3 · recruiting
NCT07142265 — Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients · recruiting
NCT07138911 — Effect of Home-based Exercise Plan Mediated by Use of Digital Health App on Kinesiophobia and Functional Capacity · NA · recruiting

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02648113 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 12 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02648113.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing